RECRUITING

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

Talk to us

Conditions

CancerChildhood CancerChemotherapy-induced Peripheral NeuropathySurvivors of childhood cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.

Official Title

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

Quick Facts

Study Start:2025-06-30
Study Completion:2026-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07019259

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:5 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * History of childhood cancer (\<21 years of age at diagnosis)
  2. * Current age five years or older (due to availability of validated measures for CIPN in this age group)
  3. * History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN
  4. * CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors \<18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)
  1. * Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)
  2. * Inability to sit still for at least 15 minutes
  3. * Diagnosis of neuropathy prior to cancer treatment
  4. * Active cancer diagnosis or cancerous skin lesion
  5. * Central nervous system tumor (due to lack of validated measures for CIPN in this population)
  6. * Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.

Contacts and Locations

Study Contact

Rozalyn Rodwin, MD
CONTACT
203-785-2407
rozalyn.rodwin@yale.edu
Jaime Rotatori, BSN, MS
CONTACT
203-785-2407
jaime.rotatori@yale.edu

Principal Investigator

Rozalyn Rodwin, MD
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

Yale New Haven Health Smilow York Street Hospital
New Haven, Connecticut, 06520
United States
Yale New Haven Health Park Avenue Medical Center
Trumbull, Connecticut, 06611
United States

Collaborators and Investigators

Sponsor: Yale University

  • Rozalyn Rodwin, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-30
Study Completion Date2026-09

Study Record Updates

Study Start Date2025-06-30
Study Completion Date2026-09

Terms related to this study

Keywords Provided by Researchers

  • Survivors of childhood cancer

Additional Relevant MeSH Terms

  • Cancer
  • Childhood Cancer
  • Chemotherapy-induced Peripheral Neuropathy